

Michelle M Mello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8558864/publications.pdf>

Version: 2024-02-01

205
papers

10,401
citations

31902

53
h-index

40881

93
g-index

206
all docs

206
docs citations

206
times ranked

9276
citing authors

#	ARTICLE	IF	CITATIONS
1	Defensive Medicine Among High-Risk Specialist Physicians in a Volatile Malpractice Environment. JAMA - Journal of the American Medical Association, 2005, 293, 2609.	3.8	957
2	Claims, Errors, and Compensation Payments in Medical Malpractice Litigation. New England Journal of Medicine, 2006, 354, 2024-2033.	13.9	722
3	National Costs Of The Medical Liability System. Health Affairs, 2010, 29, 1569-1577.	2.5	409
4	The Havasupai Indian Tribe Case â€” Lessons for Research Involving Stored Biologic Samples. New England Journal of Medicine, 2010, 363, 204-207.	13.9	320
5	Thinking Globally, Acting Locally â€” The U.S. Response to Covid-19. New England Journal of Medicine, 2020, 382, e75.	13.9	222
6	The New Medical Malpractice Crisis. New England Journal of Medicine, 2003, 348, 2281-2284.	13.9	211
7	Diagnostic Testing for the Novel Coronavirus. JAMA - Journal of the American Medical Association, 2020, 323, 1437.	3.8	209
8	Financial Conflicts of Interest in Physicians' Relationships with the Pharmaceutical Industry â€” Self-Regulation in the Shadow of Federal Prosecution. New England Journal of Medicine, 2004, 351, 1891-1900.	13.9	198
9	Conflict in the care of patients with prolonged stay in the ICU: types, sources, and predictors. Intensive Care Medicine, 2003, 29, 1489-1497.	3.9	192
10	The Role of Medical Liability Reform in Federal Health Care Reform. New England Journal of Medicine, 2009, 361, 1-3.	13.9	185
11	Obesity â€” The New Frontier of Public Health Law. New England Journal of Medicine, 2006, 354, 2601-2610.	13.9	181
12	Relationship Between Malpractice Litigation Pressure and Rates of Cesarean Section and Vaginal Birth After Cesarean Section. Medical Care, 2009, 47, 234-242.	1.1	175
13	Clinical Trial Participantsâ€™ Views of the Risks and Benefits of Data Sharing. New England Journal of Medicine, 2018, 378, 2202-2211.	13.9	162
14	Making the Case for Laws That Improve Health: A Framework for Public Health Law Research. Milbank Quarterly, 2010, 88, 169-210.	2.1	156
15	Preparing for Responsible Sharing of Clinical Trial Data. New England Journal of Medicine, 2013, 369, 1651-1658.	13.9	155
16	Nature of Conflict in the Care of Pediatric Intensive Care Patients With Prolonged Stay. Pediatrics, 2003, 112, 553-558.	1.0	141
17	Academic Medical Centers' Standards for Clinical-Trial Agreements with Industry. New England Journal of Medicine, 2005, 352, 2202-2210.	13.9	121
18	HIPAA and Protecting Health Information in the 21st Century. JAMA - Journal of the American Medical Association, 2018, 320, 231.	3.8	118

#	ARTICLE	IF	CITATIONS
19	Prevalence and Characteristics of Physicians Prone to Malpractice Claims. <i>New England Journal of Medicine</i> , 2016, 374, 354-362.	13.9	114
20	Implementing Resident Work Hour Limitations. <i>Annals of Surgery</i> , 2003, 237, 449-455.	2.1	109
21	Disclosure Of Medical Injury To Patients: An Improbable Risk Management Strategy. <i>Health Affairs</i> , 2007, 26, 215-226.	2.5	108
22	Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. <i>Lancet</i> , The, 2021, 398, 2186-2192.	6.3	106
23	Results of a clinical trial on care improvement for the critically ill. <i>Critical Care Medicine</i> , 2003, 31, 2107-2117.	0.4	101
24	New Directions in Medical Liability Reform. <i>New England Journal of Medicine</i> , 2011, 364, 1564-1572.	13.9	97
25	Work hours reform: perceptions and desires of contemporary surgical residents. <i>Journal of the American College of Surgeons</i> , 2003, 197, 624-630.	0.2	96
26	A New Era in Noninvasive Prenatal Testing. <i>New England Journal of Medicine</i> , 2013, 369, 499-501.	13.9	93
27	HPV Vaccination Mandates " Lawmaking amid Political and Scientific Controversy. <i>New England Journal of Medicine</i> , 2010, 363, 785-791.	13.9	90
28	Medical Malpractice Liability in the Age of Electronic Health Records. <i>New England Journal of Medicine</i> , 2010, 363, 2060-2067.	13.9	89
29	Strategies and Practices in Off-Label Marketing of Pharmaceuticals: A Retrospective Analysis of Whistleblower Complaints. <i>PLoS Medicine</i> , 2011, 8, e1000431.	3.9	88
30	Half-Baked " The Retail Promotion of Marijuana Edibles. <i>New England Journal of Medicine</i> , 2015, 372, 989-991.	13.9	88
31	Caring For Patients In A Malpractice Crisis: Physician Satisfaction And Quality Of Care. <i>Health Affairs</i> , 2004, 23, 42-53.	2.5	87
32	Ethics and governance for digital disease surveillance. <i>Science</i> , 2020, 368, 951-954.	6.0	87
33	Big Data, Big Tech, and Protecting Patient Privacy. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1141.	3.8	85
34	Do Medicare HMOs still reduce health services use after controlling for selection bias?. <i>Health Economics (United Kingdom)</i> , 2002, 11, 323-340.	0.8	83
35	Understanding Biased Selection in Medicare HMOs. <i>Health Services Research</i> , 2003, 38, 961-992.	1.0	79
36	Communication-And-Resolution Programs: The Challenges And Lessons Learned From Six Early Adopters. <i>Health Affairs</i> , 2014, 33, 20-29.	2.5	78

#	ARTICLE	IF	CITATIONS
37	Ensuring Uptake of Vaccines against SARS-CoV-2. <i>New England Journal of Medicine</i> , 2020, 383, 1296-1299.	13.9	77
38	The Medical Liability Climate and Prospects for Reform. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2146.	3.8	75
39	The Interplay of Public Health Law and Industry Self-Regulation: The Case of Sugar-Sweetened Beverage Sales in Schools. <i>American Journal of Public Health</i> , 2008, 98, 595-604.	1.5	74
40	Regulation of Smoking in Public Housing. <i>New England Journal of Medicine</i> , 2010, 362, 2319-2325.	13.9	73
41	Effects of a Malpractice Crisis on Specialist Supply and Patient Access to Care. <i>Annals of Surgery</i> , 2005, 242, 621-628.	2.1	69
42	THE ROLE OF CLINICAL GUIDELINES IN MEDICAL NEGLIGENCE LITIGATION: A SHIFT FROM THE BOLAM STANDARD?. <i>Medical Law Review</i> , 2006, 14, 321-366.	0.2	69
43	The Flaws In State "Apology" And "Disclosure" Laws Dilute Their Intended Impact On Malpractice Suits. <i>Health Affairs</i> , 2010, 29, 1611-1619.	2.5	69
44	Shifting Vaccination Politics " The End of Personal-Belief Exemptions in California. <i>New England Journal of Medicine</i> , 2015, 373, 785-787.	13.9	68
45	The Rise of Litigation in Human Subjects Research. <i>Annals of Internal Medicine</i> , 2003, 139, 40.	2.0	67
46	Talking with Patients about Other Clinicians' Errors. <i>New England Journal of Medicine</i> , 2013, 369, 1752-1757.	13.9	67
47	Wellness Programs and Lifestyle Discrimination " The Legal Limits. <i>New England Journal of Medicine</i> , 2008, 359, 192-199.	13.9	66
48	Sunlight as Disinfectant " New Rules on Disclosure of Industry Payments to Physicians. <i>New England Journal of Medicine</i> , 2013, 368, 2052-2054.	13.9	63
49	Legal Barriers to the Growth of Health Information Exchange"Boulders or Pebbles?. <i>Milbank Quarterly</i> , 2018, 96, 110-143.	2.1	63
50	Sociodemographic Predictors of Vaccination Exemptions on the Basis of Personal Belief in California. <i>American Journal of Public Health</i> , 2016, 106, 172-177.	1.5	62
51	Public Awareness of and Contact With Physicians Who Receive Industry Payments: A National Survey. <i>Journal of General Internal Medicine</i> , 2017, 32, 767-774.	1.3	62
52	Association of Overlapping Surgery With Perioperative Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 762.	3.8	62
53	"Health Courts" and Accountability for Patient Safety. <i>Milbank Quarterly</i> , 2006, 84, 459-492.	2.1	58
54	Gene Patenting " The Supreme Court Finally Speaks. <i>New England Journal of Medicine</i> , 2013, 369, 869-875.	13.9	58

#	ARTICLE	IF	CITATIONS
55	Attacks on Public Health Officials During COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 741.	3.8	58
56	The McLawsuit: The Fast-Food Industry And Legal Accountability For Obesity. Health Affairs, 2003, 22, 207-216.	2.5	55
57	Drug Companiesâ€™ Liability for the Opioid Epidemic. New England Journal of Medicine, 2017, 377, 2301-2305.	13.9	54
58	Managing the Risks of Concurrent Surgeries. JAMA - Journal of the American Medical Association, 2016, 315, 1563.	3.8	52
59	Shifting Terrain in the Regulation of Off-Label Promotion of Pharmaceuticals. New England Journal of Medicine, 2009, 360, 1557-1566.	13.9	51
60	Patientsâ€™ Experiences With Communication-and-Resolution Programs After Medical Injury. JAMA Internal Medicine, 2017, 177, 1595.	2.6	50
61	Assessment of Out-of-Network Billing for Privately Insured Patients Receiving Care in In-Network Hospitals. JAMA Internal Medicine, 2019, 179, 1543.	2.6	50
62	Whistle-Blowers' Experiences in Fraud Litigation against Pharmaceutical Companies. New England Journal of Medicine, 2010, 362, 1832-1839.	13.9	46
63	Disclosure, Apology, and Offer Programs: Stakeholdersâ€™ Views of Barriers to and Strategies for Broad Implementation. Milbank Quarterly, 2012, 90, 682-705.	2.1	46
64	Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies. BMJ Open, 2017, 7, e017917.	0.8	46
65	Respecting Disability Rights â€” Toward Improved Crisis Standards of Care. New England Journal of Medicine, 2020, 383, e26.	13.9	44
66	Malpractice Liability and Health Care Quality. JAMA - Journal of the American Medical Association, 2020, 323, 352.	3.8	44
67	Malpractice Reform â€” Opportunities for Leadership by Health Care Institutions and Liability Insurers. New England Journal of Medicine, 2010, 362, 1353-1356.	13.9	43
68	Have Tobacco 21 Laws Come of Age?. New England Journal of Medicine, 2016, 374, 1601-1604.	13.9	40
69	Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices. BMJ: British Medical Journal, 2019, 366, l4217.	2.4	40
70	US Nationwide Disclosure of Industry Payments and Public Trust in Physicians. JAMA Network Open, 2019, 2, e191947.	2.8	40
71	Tobacco 21 â€” An Idea Whose Time Has Come. New England Journal of Medicine, 2014, 370, 295-297.	13.9	39
72	Who Pays for Medical Errors? An Analysis of Adverse Event Costs, the Medical Liability System, and Incentives for Patient Safety Improvement. Journal of Empirical Legal Studies, 2007, 4, 835-860.	0.5	38

#	ARTICLE	IF	CITATIONS
73	New York City's War on Fat. <i>New England Journal of Medicine</i> , 2009, 360, 2015-2020.	13.9	38
74	Effects of a Professional Liability Crisis on Residents' Practice Decisions. <i>Obstetrics and Gynecology</i> , 2005, 105, 1287-1295.	1.2	37
75	Pharmaceutical Companies' Role in State Vaccination Policymaking: The Case of Human Papillomavirus Vaccination. <i>American Journal of Public Health</i> , 2012, 102, 893-898.	1.5	37
76	The Politics of HPV Vaccination Policy Formation in the United States. <i>Journal of Health Politics, Policy and Law</i> , 2013, 38, 645-681.	0.9	37
77	How Policy Makers Can Smooth The Way For Communication-And- Resolution Programs. <i>Health Affairs</i> , 2014, 33, 11-19.	2.5	36
78	What Is a Public Health "Emergency"? <i>New England Journal of Medicine</i> , 2014, 371, 986-988.	13.9	36
79	Disclosing Harmful Medical Errors to Patients. <i>Chest</i> , 2009, 136, 897-903.	0.4	35
80	Relationship between Quality of Care and Negligence Litigation in Nursing Homes. <i>New England Journal of Medicine</i> , 2011, 364, 1243-1250.	13.9	34
81	Improving reconciliation following medical injury: a qualitative study of responses to patient safety incidents in New Zealand. <i>BMJ Quality and Safety</i> , 2017, 26, 788-798.	1.8	34
82	Effects Of A Communication-And-Resolution Program On Hospitals' Malpractice Claims And Costs. <i>Health Affairs</i> , 2018, 37, 1836-1844.	2.5	32
83	The Evolving Story of Overlapping Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 233.	3.8	31
84	Effect of the public disclosure of industry payments information on patients: results from a population-based natural experiment. <i>BMJ Open</i> , 2019, 9, e024020.	0.8	31
85	Fostering Rational Regulation of Patient Safety. <i>Journal of Health Politics, Policy and Law</i> , 2005, 30, 375-426.	0.9	30
86	Defensive Medicine and Tort Reform: A Wide View. <i>Journal of General Internal Medicine</i> , 2010, 25, 380-381.	1.3	30
87	Patient Safety and Medical Malpractice: A Case Study. <i>Annals of Internal Medicine</i> , 2003, 139, 267.	2.0	29
88	Geographic Variation in Informed Consent Law: Two Standards for Disclosure of Treatment Risks. <i>Journal of Empirical Legal Studies</i> , 2007, 4, 103-124.	0.5	29
89	Standing Up against Gender Bias and Harassment " A Matter of Professional Ethics. <i>New England Journal of Medicine</i> , 2020, 382, 1385-1387.	13.9	28
90	Disclosure-And-Resolution Programs That Include Generous Compensation Offers May Prompt A Complex Patient Response. <i>Health Affairs</i> , 2012, 31, 2681-2689.	2.5	27

#	ARTICLE	IF	CITATIONS
91	A Longitudinal Analysis of the Impact of Liability Pressure on the Supply of Obstetrician-Gynecologists. <i>Journal of Empirical Legal Studies</i> , 2008, 5, 21-53.	0.5	26
92	Searching for Public Health Law's Sweet Spot: The Regulation of Sugar-Sweetened Beverages. <i>PLoS Medicine</i> , 2015, 12, e1001848.	3.9	26
93	Critical Opportunities for Public Health Law: A Call for Action. <i>American Journal of Public Health</i> , 2013, 103, 1979-1988.	1.5	25
94	Implementing Hospital-Based Communication-And-Resolution Programs: Lessons Learned In New York City. <i>Health Affairs</i> , 2014, 33, 30-38.	2.5	25
95	Outcomes In Two Massachusetts Hospital Systems Give Reason For Optimism About Communication-And-Resolution Programs. <i>Health Affairs</i> , 2017, 36, 1795-1803.	2.5	25
96	Announcing the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. <i>Lancet</i> , The, 2021, 397, 1165-1167.	6.3	25
97	Medical malpractice as an epidemiological problem. <i>Social Science and Medicine</i> , 2004, 59, 39-46.	1.8	24
98	Changes In Physician Supply And Scope Of Practice During A Malpractice Crisis: Evidence From Pennsylvania. <i>Health Affairs</i> , 2007, 26, w425-w435.	2.5	24
99	RATIONALIZING VACCINE INJURY COMPENSATION. <i>Bioethics</i> , 2008, 22, 32-42.	0.7	24
100	Federal Trade Commission Regulation of Food Advertising to Children: Possibilities for a Reinvigorated Role. <i>Journal of Health Politics, Policy and Law</i> , 2010, 35, 227-276.	0.9	24
101	The Missing Piece " SARS-CoV-2 Testing and School Reopening. <i>New England Journal of Medicine</i> , 2020, 383, e126.	13.9	24
102	Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs. <i>JAMA Network Open</i> , 2021, 4, e217075.	2.8	24
103	Due Process in Investigations of Research Misconduct. <i>New England Journal of Medicine</i> , 2003, 349, 1280-1286.	13.9	23
104	"Pay for Delay" Settlements of Disputes over Pharmaceutical Patents. <i>New England Journal of Medicine</i> , 2011, 365, 1439-1445.	13.9	23
105	Does Tort Law Improve the Health of Newborns, or Miscarry? A Longitudinal Analysis of the Effect of Liability Pressure on Birth Outcomes. <i>Journal of Empirical Legal Studies</i> , 2012, 9, 217-245.	0.5	23
106	Can Communication-And-Resolution Programs Achieve Their Potential? Five Key Questions. <i>Health Affairs</i> , 2018, 37, 1845-1852.	2.5	22
107	Partitioning the Curve " Interstate Travel Restrictions During the Covid-19 Pandemic. <i>New England Journal of Medicine</i> , 2020, 383, e83.	13.9	22
108	Reduced Medicolegal Risk by Compliance With Obstetric Clinical Pathways. <i>Obstetrics and Gynecology</i> , 2003, 101, 751-755.	1.2	21

#	ARTICLE	IF	CITATIONS
109	Gene Patenting “Is the Pendulum Swinging Back?. New England Journal of Medicine, 2010, 362, 1855-1858.	13.9	21
110	Ethical Considerations in Studying Drug Safety “The Institute of Medicine Report. New England Journal of Medicine, 2012, 367, 959-964.	13.9	21
111	Defensive Medicine“Legally Necessary but Ethically Wrong?. JAMA Internal Medicine, 2013, 173, 1056.	2.6	21
112	Decision making and satisfaction with care in the pediatric intensive care unit: Findings from a controlled clinical trial. Pediatric Critical Care Medicine, 2004, 5, 40-47.	0.2	20
113	Challenges of Implementing a Communication“and“Resolution Program Where Multiple Organizations Must Cooperate. Health Services Research, 2016, 51, 2550-2568.	1.0	20
114	Behind Schedule “Reconciling Federal and State Marijuana Policy. New England Journal of Medicine, 2018, 379, 501-504.	13.9	20
115	Changes in Practice among Physicians with Malpractice Claims. New England Journal of Medicine, 2019, 380, 1247-1255.	13.9	20
116	Direct-to-Consumer Advertising and Shared Liability for Pharmaceutical Manufacturers. JAMA - Journal of the American Medical Association, 2003, 289, 477.	3.8	19
117	Restrictions on the Use of Prescribing Data for Drug Promotion. New England Journal of Medicine, 2011, 365, 1248-1254.	13.9	19
118	The Leapfrog Standards: Ready To Jump From Marketplace To Courtroom?. Health Affairs, 2003, 22, 46-59.	2.5	18
119	A New Era in Noninvasive Prenatal Testing. New England Journal of Medicine, 2013, 369, 2164-2165.	13.9	18
120	Legal and Policy Interventions to Improve Patient Safety. Circulation, 2016, 133, 661-671.	1.6	18
121	Protecting the Privacy of Reproductive Health Information After the Fall of <i>Roe v Wade</i> . JAMA Health Forum, 2022, 3, e222656.	1.0	18
122	Hospitals“™ Behavior In A Tort Crisis: Observations From Pennsylvania. Health Affairs, 2003, 22, 225-233.	2.5	17
123	The Pharmaceutical Industry versus Medicaid “Limits on State Initiatives to Control Prescription-Drug Costs. New England Journal of Medicine, 2004, 350, 608-613.	13.9	17
124	Sunshine Laws and the Pharmaceutical Industry. JAMA - Journal of the American Medical Association, 2007, 297, 1255.	3.8	17
125	Administrative Compensation of Medical Injuries: A Hardy Perennial Blooms Again. Journal of Health Politics, Policy and Law, 2008, 33, 725-760.	0.9	17
126	Incentives for COVID-19 vaccination. The Lancet Regional Health Americas, 2022, 8, 100205.	1.5	17

#	ARTICLE	IF	CITATIONS
127	The Future of Surgery: Today's Residents Speak. <i>Journal of Surgical Education</i> , 2005, 62, 543-546.	0.7	16
128	Medical-Process Patents " Monopolizing the Delivery of Health Care. <i>New England Journal of Medicine</i> , 2006, 355, 2036-2041.	13.9	16
129	Adjudicating Severe Birth Injury Claims in Florida and Virginia: The Experience of a Landmark Experiment in Personal Injury Compensation. <i>American Journal of Law and Medicine</i> , 2008, 34, 493-537.	0.5	16
130	Breast Cancer Screening. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 2555.	3.8	16
131	Association Between State Medical Malpractice Environment and Surgical Quality and Cost in the United States. <i>Annals of Surgery</i> , 2016, 263, 1126-1132.	2.1	16
132	Legal Concerns and the Influenza Vaccine Shortage. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 1817.	3.8	15
133	Case Outcomes in a Communication-and-Resolution Program in New York Hospitals. <i>Health Services Research</i> , 2016, 51, 2583-2599.	1.0	15
134	Waiting for data: Barriers to executing data use agreements. <i>Science</i> , 2020, 367, 150-152.	6.0	15
135	Compact versus Contract " Industry Sponsors' Obligations to Their Research Subjects. <i>New England Journal of Medicine</i> , 2007, 356, 2737-2743.	13.9	14
136	Choices in a Crisis " Individual Preferences among SARS-CoV-2 Vaccines. <i>New England Journal of Medicine</i> , 2021, 384, e62.	13.9	14
137	Public Health Law after Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 1153-1155.	13.9	13
138	Researchers' Views of the Acceptability of Restrictive Provisions in Clinical Trial Agreements with Industry Sponsors. <i>Accountability in Research</i> , 2005, 12, 163-191.	1.6	12
139	Medical Liability " Prospects for Federal Reform. <i>New England Journal of Medicine</i> , 2017, 376, 1806-1808.	13.9	12
140	Vaccination without Litigation " Addressing Religious Objections to Hospital Influenza-Vaccination Mandates. <i>New England Journal of Medicine</i> , 2018, 378, 785-788.	13.9	12
141	Ethics of randomized trials in a public health emergency. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006313.	1.3	12
142	Incorporating Health Equity Into COVID-19 Reopening Plans: Policy Experimentation in California. <i>American Journal of Public Health</i> , 2021, 111, 1481-1488.	1.5	12
143	Administrative compensation for medical injuries: lessons from three foreign systems. <i>Issue Brief (Commonwealth Fund)</i> , 2011, 14, 1-18.	0.9	12
144	FDA Regulation of Off-label Drug Promotion Under Attack. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 445.	3.8	11

#	ARTICLE	IF	CITATIONS
145	Collaboration with Regulators to Support Quality and Accountability Following Medical Errors: The Communication and Resolution Program Certification Pilot. <i>Health Services Research</i> , 2016, 51, 2569-2582.	1.0	11
146	Ensuring successful implementation of communication-and-resolution programmes. <i>BMJ Quality and Safety</i> , 2020, 29, 895-904.	1.8	11
147	School Reopenings and the Community During the COVID-19 Pandemic. <i>JAMA Health Forum</i> , 2020, 1, e201294.	1.0	11
148	The Legal Authority for Statesâ€™ Stay-at-Home Orders. <i>New England Journal of Medicine</i> , 2020, 383, e29.	13.9	10
149	Assessment of Perioperative Outcomes Among Surgeons Who Operated the Night Before. <i>JAMA Internal Medicine</i> , 2022, 182, 720.	2.6	10
150	Obesityâ€™ personal choice or public health issue?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 2-3.	2.9	9
151	New horizons in pharmaceutical regulation. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 501-502.	21.5	8
152	Building a National Surveillance System for Malpractice Claims. <i>Health Services Research</i> , 2016, 51, 2642-2648.	1.0	8
153	How US law will evaluate artificial intelligence for covid-19. <i>BMJ, The</i> , 2021, 372, n234.	3.0	8
154	Clinical trial transparency and data sharing among biopharmaceutical companies and the role of company size, location and product type: a cross-sectional descriptive analysis. <i>BMJ Open</i> , 2021, 11, e053248.	0.8	8
155	Regulatory and Judicial Oversight of Nonprofit Hospitals. <i>New England Journal of Medicine</i> , 2007, 356, 625-631.	13.9	7
156	Supporting Those Who Go to Fight Ebola. <i>PLoS Medicine</i> , 2015, 12, e1001781.	3.9	7
157	When Physicians Engage in Practices That Threaten the Nationâ€™s Health. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 723.	3.8	7
158	Policing Medicaid and Medicare Managed Care: The Role of Courts and Administrative Agencies. <i>Journal of Health Politics, Policy and Law</i> , 2002, 27, 465-494.	0.9	6
159	In search of global governance for research in epidemics. <i>Lancet, The</i> , 2017, 390, 1632-1633.	6.3	6
160	Multilevel legal approaches to obesity prevention: A conceptual and methodological toolkit. <i>PLoS ONE</i> , 2019, 14, e0220971.	1.1	6
161	U.S. Public Health Law â€™ Foundations and Emerging Shifts. <i>New England Journal of Medicine</i> , 2022, 386, 805-808.	13.9	6
162	Medical Monitoring for Pharmaceutical Injuries. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 889.	3.8	5

#	ARTICLE	IF	CITATIONS
163	Legal and policy approaches to the obesity epidemic. <i>Surgery for Obesity and Related Diseases</i> , 2012, 8, 507-513.	1.0	5
164	Should Malpractice Settlements Be Secret?. <i>JAMA Internal Medicine</i> , 2015, 175, 1135.	2.6	5
165	Disclosing Prescription-Drug Prices in Advertisements â€” Legal and Public Health Issues. <i>New England Journal of Medicine</i> , 2018, 379, 2290-2293.	13.9	5
166	Beyond financial conflicts of interest: Institutional oversight of faculty consulting agreements at schools of medicine and public health. <i>PLoS ONE</i> , 2018, 13, e0203179.	1.1	5
167	Barriers to Ensuring Access to Affordable Prescription Drugs. <i>Annual Review of Pharmacology and Toxicology</i> , 2020, 60, 275-289.	4.2	5
168	Apology laws and malpractice liability: what have we learned?. <i>BMJ Quality and Safety</i> , 2021, 30, 64-67.	1.8	5
169	Do you mind if I record?: Perceptions and practice regarding patient requests to record clinic visits in oncology. <i>Cancer</i> , 2022, 128, 275-283.	2.0	5
170	Vaccine Misinformation and the First Amendmentâ€™The Price of Free Speech. <i>JAMA Health Forum</i> , 2022, 3, e220732.	1.0	5
171	Institutional Oversight of Faculty-Industry Consulting Relationships in U.S. Medical Schools: A Delphi Study. <i>Journal of Law, Medicine and Ethics</i> , 2015, 43, 383-96.	0.4	5
172	Testing the Immunity of the Firearm Industry to Tort Litigation. <i>JAMA Internal Medicine</i> , 2017, 177, 102.	2.6	4
173	Liability, Patient Safety, and Defensive Medicine: What Does the Future Hold?. , 2006, , 93-114.		3
174	Incremental Health Care Reform. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1814.	3.8	3
175	Medical Malpractice in the Military. <i>New England Journal of Medicine</i> , 2011, 365, 664-670.	13.9	3
176	Medical Malpractice Liability in the Age of Electronic Health Records. <i>Survey of Anesthesiology</i> , 2011, 55, 317-319.	0.1	3
177	Making the Case for Health-Enhancing Laws after Bloomberg. <i>Hastings Center Report</i> , 2014, 44, 8-8.	0.7	3
178	When are primary care physicians untruthful with patients? A qualitative study. <i>AJOB Empirical Bioethics</i> , 2017, 8, 32-39.	0.8	3
179	Commentary: How Should Hospitals Respond to Surgeonsâ€™ Requests to Schedule Overlapping Surgeries?. <i>Neurosurgery</i> , 2018, 82, E91-E98.	0.6	3
180	â€”Poking the skunkâ€™: Ethical and medicoâ€”legal concerns in research about patientsâ€™ experiences of medical injury. <i>Bioethics</i> , 2019, 33, 948-957.	0.7	3

#	ARTICLE	IF	CITATIONS
181	Narrowing Vaccination Exemption Laws: Lessons From California and Beyond. <i>Annals of Internal Medicine</i> , 2020, 172, 358.	2.0	3
182	Prospects for Enforcing Prohibitions on Off-Label Drug Promotion after <i>United States v. Caronia</i> : An Analysis of Litigated Cases. <i>Journal of Health Politics, Policy and Law</i> , 2021, 46, 487-504.	0.9	3
183	Population health science as a unifying foundation for translational clinical and public health research. <i>SSM - Population Health</i> , 2022, 18, 101047.	1.3	3
184	The Taxing Power and the Public's Health. <i>New England Journal of Medicine</i> , 2012, 367, 1777-1779.	13.9	2
185	Medical Liability and Reporting Malpractice Payments—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1058.	3.8	2
186	Association of Federal Mental Health Parity Legislation With Health Care Use and Spending Among High Utilizers of Services. <i>Medical Care</i> , 2019, 57, 245-255.	1.1	2
187	To Address Drug Affordability, Grab the Low-hanging Fruit. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1599.	3.8	2
188	Drug Pricing Reform in 2021—Going Big or Going Bipartisan?. <i>JAMA Health Forum</i> , 2021, 2, e212372.	1.0	2
189	Managing Malpractice Crises. <i>Journal of Law, Medicine and Ethics</i> , 2005, 33, 414-415.	0.4	1
190	Commentary: A Legal Perspective on Diabetes Surveillance—Privacy and the Police Power. <i>Milbank Quarterly</i> , 2009, 87, 575-580.	2.1	1
191	Ejecting trans fat from New York City restaurants. <i>Nature Reviews Endocrinology</i> , 2012, 8, 633-635.	4.3	1
192	Clinical Trials and the Right to Remain Silent. <i>JAMA Internal Medicine</i> , 2014, 174, 1505.	2.6	1
193	Demystifying the Law/Science Disconnect. <i>Journal of Health Politics, Policy and Law</i> , 2001, 26, 429-438.	0.9	1
194	The Political and Judicial Battles Over Mask Mandates for Schools. <i>JAMA Health Forum</i> , 2021, 2, e214192.	1.0	1
195	The experience of a community representative on an ethics consult team. <i>Journal of Clinical Ethics</i> , 2004, 15, 296-301.	0.1	1
196	Malpractice Reform—Opportunities for Leadership by Health Care Institutions and Liability Insurers. <i>Obstetrics and Gynecology</i> , 2010, 116, 1254-1256.	1.2	0
197	Editors' Introduction. <i>Journal of Health Politics, Policy and Law</i> , 2013, 38, 629-643.	0.9	0
198	Association of Unsolicited Patient Observations With the Quality of a Surgeon's Care. <i>JAMA Surgery</i> , 2017, 152, 530.	2.2	0

#	ARTICLE	IF	CITATIONS
199	Length of Stay After Overlapping Surgeryâ€™Reply. JAMA - Journal of the American Medical Association, 2017, 318, 2140.	3.8	0
200	What Patients Expect and Deserveâ€™Reply. JAMA Internal Medicine, 2018, 178, 578.	2.6	0
201	The Role of Transparency in Patient Safety Improvement. , 2019, , 244-259.		0
202	To Address Drug Affordability, Grab the Low-Hanging Fruit. JAMA Health Forum, 2021, 2, e210260.	1.0	0
203	Supporting Hospitals During a New Wave of COVID-19. Journal of Hospital Medicine, 2021, 16, 311-312.	0.7	0
204	The Medical Liability Environment: Is It Really Any Worse for Hospitalists?. Journal of Hospital Medicine, 2021, 16, 446.	0.7	0
205	Oncologist experiences regarding patient-recorded clinical encounters: Implications for the patient-doctor relationship.. Journal of Clinical Oncology, 2020, 38, 290-290.	0.8	0